Alembic Pharmaceuticals Limited Share Price & Analysis

Alembic Pharma gets USFDA tentative nod for Binimetinib tablets

*Alembic Pharma gets USFDA tentative nod for Binimetinib tablets* — Alembic Pharmaceuticals has received tentative approval from the USFDA for its Binimetinib Tablets, 45 mg. The drug is a generic version of Novartis’ Mektovi tablets, used for treating melanoma. Tentative approval means the product can launch upon patent expiry or final regulatory clearance. This positions Alembic to enter the US market early and gain revenue momentum. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA nod for Tretinoin Cream 0.05%

*Alembic Pharma gets USFDA nod for Tretinoin Cream 0.05%*. Alembic Pharmaceuticals has received final approval from the USFDA for Tretinoin Cream USP, **0.05%**, used for topical dermatological treatment. This approval allows the company to market the generic version in the US, expanding its dermatology portfolio. The product is therapeutically equivalent to the reference listed drug. 📊 *STOCKS:* APLLTB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA tentative nod for cancer drug

*Alembic Pharma gets USFDA tentative nod for cancer drug* — Alembic Pharmaceuticals has received tentative approval from the USFDA for Larotrectinib Capsules, 25 mg and 100 mg. The drug is used for the treatment of certain solid tumors in adults and children. Tentative approval indicates the product meets quality, safety, and efficacy standards, pending final regulatory steps. Commercial launch will follow final approval and patent expiries. 📊 *STOCKS:* APLLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Ltd to hold shareholder meeting on August 11, 2026

*Alembic Ltd to hold shareholder meeting on August 11, 2026* — as per a corporate filing. The agenda and key resolutions, if any, are yet to be disclosed. Such meetings typically precede strategic announcements or governance updates. No financial impact expected unless major decisions are revealed. 📊 *STOCKS:* ALEMBICLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting

Alembic Pharma gets USFDA nod for Dapsone Gel 5%

*Alembic Pharma gets USFDA nod for Dapsone Gel 5%* Alembic Pharmaceuticals has received USFDA approval for Dapsone Gel 5%, a topical treatment for acne. The product will be marketed in the US market, expanding its dermatology portfolio. This approval positions APLLTD to tap into the growing demand for acne therapeutics. The US launch will be under its subsidiary, Alembic Pharmaceuticals Inc. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA approval for flu drug

*Alembic Pharma gets USFDA nod for generic influenza treatment drug.* This approval allows the company to launch the generic version of a flu medication in the US market. Entry into the competitive US generics space could boost revenues by **$50–70 million** annually at peak. The stock may see positive momentum on export potential. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA nod for generic cancer drug

*Alembic Pharma gets USFDA tentative approval for generic cancer drug.* This clears a key regulatory hurdle for market entry in the US. The drug will compete with **branded versions**, potentially boosting revenue once fully approved. Tentative approval allows Alembic to launch upon patent expiry. 📊 *STOCKS:* APLLTB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma gets USFDA nod for Tretinoin cream

*Alembic Pharma gets USFDA nod for Tretinoin cream* Alembic Pharmaceuticals has received final approval from the USFDA for Tretinoin Cream USP, 0.05%. The product is a generic version of Avita Cream, used for acne treatment. This approval expands Alembic’s dermatology portfolio in the US market. 📊 *STOCKS:* ALPH | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic gets USFDA tentative nod for cancer drug

*Alembic gets USFDA tentative nod for cancer drug* Alembic Pharmaceuticals received tentative approval from the USFDA for its Larotrectinib Capsules, a generic version of Vitrakvi. The drug is used for treating NTRK gene fusion-positive cancers. Tentative approval means the product meets quality standards but cannot be launched until patent expiry. Final approval and market entry depend on intellectual property timelines. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Alembic Pharma publishes statutory newspaper notice

*Alembic Pharma publishes statutory newspaper notice.* The company has released a copy of its newspaper publication as part of regulatory compliance. This is a routine corporate disclosure with no operational or financial implications. No material business updates were included. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate